Condition
First Line Treatment
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Completed2
Not Yet Recruiting2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07500298Phase 1Not Yet Recruiting
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
NCT06981325Phase 2Recruiting
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
NCT06374160Not ApplicableNot Yet Recruiting
Exercise in Patients With Advanced Non-small Cell Lung Cancer
NCT01980212Completed
Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer
NCT02055508Not ApplicableCompleted
POSITIVE - Study (Part III) Heidelberg
Showing all 5 trials